Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. - Wikidata - wikimedia - TriplyDB

Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic.

Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic.

http://www.wikidata.org/entity/Q36404922

about

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis Use of rifaximin in gastrointestinal and liver diseases Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis Efficacy, safety, and applicability of outpatient treatment for diverticulitis Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats.Small intestinal bacterial overgrowth: diagnosis and treatment.Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial.Italian consensus conference for colonic diverticulosis and diverticular disease.Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers.Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents.Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites Rifaximin Is Effective for the Treatment of Clostridium difficile-Associated Diarrhea: Results of an Open-Label Pilot Study.Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects.Pathophysiology and Therapeutic Strategies for Symptomatic Uncomplicated Diverticular Disease of the Colon.Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases.Rifaximin is an effective alternative to metronidazole for the treatment of chronic enteropathy in dogs: a randomised trial.Advances in the management of colonic diverticulitis.Preventing recurrent acute diverticulitis with pharmacological therapies A randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in the treatment of tropical enteropathy.Pros and cons of antibiotic therapy for pouchitis.Pharmacotherapy of hepatic encephalopathy in cirrhosis.Treatment options for hepatic encephalopathy.The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis.Agents that act luminally to treat diarrhoea and constipation.Rifaximin: recent advances in gastroenterology and hepatology Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome.Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.Rifaximin in the management of colonic diverticular disease.Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation Rosacea and gastrointestinal disorders: a population-based cohort study.Rifaximin Improves Clostridium difficile Toxin A-Induced Toxicity in Caco-2 Cells by the PXR-Dependent TLR4/MyD88/NF-κB Pathway Therapeutic Success of Rifaximin for Clostridium difficile Infection Refractory to Metronidazole and Vancomycin.Rifaximin therapy and hepatic encephalopathy: Pros and cons.Rifaximin for the treatment of hepatic encephalopathy.Rifaximin diminishes neutropenia following potentially lethal whole-body radiation.Microbial manipulation as primary therapy for Crohn's disease.Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximin.Rifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship.Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial.

P2860

Q21261868-6A680FF5-17AC-44F1-B02C-28213126F457 Q26740201-FBE2B4C7-1527-4A63-B7F9-DCE5817B92EF Q26778000-A3C3C56A-409D-4A3E-8817-9C98E9C5FD16 Q26862067-2C202411-2A87-49DB-91CD-42006FA458A5 Q28280394-63AEC074-D910-4758-907E-A0A8F9D184C9 Q31142368-5D83071F-E147-4FED-9EB8-7F5BB68193EF Q33438120-AFE2C1E6-9B12-431E-A70D-31BA98534557 Q34409185-81601827-A3F5-43D4-B517-9FA05B9498C9 Q34418890-F05A4282-76A2-42E6-987D-7165FCE71645 Q34757166-E7D8D8A9-EA7B-4F3F-8AAE-070A9BDD6BBC Q35018460-2C578916-937B-4697-BDF9-A7E45E72E550 Q35143004-69D97F09-6CEA-4A8C-931B-15559AFBB7C8 Q35550741-E5DFB36E-F3E7-4BED-BD8F-D471391104D0 Q35649153-1B48608F-5682-4D2F-9467-6B969CA8D157 Q35803757-37DFC699-D1A6-40B6-878B-78B0C408A468 Q35855737-5B63C229-E9FE-4B8D-A9E0-3B55E40DC6BF Q36157264-33E92B59-6B14-4F63-A2AF-802626FBF61E Q36247374-5FB924BE-7B8C-47FA-9C5C-729BDBD93383 Q37253907-5CB7EE4C-3701-4D04-8968-27AE443761EC Q37378938-721B57AC-1ABF-41C7-B6CD-0173A59F073E Q37611860-D89C2D43-C86E-498D-98EE-8C36D6DDA281 Q37729173-394AC2B0-E6CF-43EE-82C7-68059EEBF9E4 Q37735854-79602D03-F2F4-4B82-8207-BDC9A6420782 Q37951770-A77F231B-FDD3-41ED-A729-DFA5CF527E10 Q38040321-203E43B6-7991-42D1-AEA3-F75A67D35055 Q38074951-8772300B-DFDE-41F9-B883-DBEFB2112EC8 Q38340085-D2030823-F814-4ECA-B4BC-5F1CD5C6E8A6 Q38692607-36644D25-0D0B-4C0E-BC16-398EB310FEDE Q39295479-B42193A3-5140-44DB-AA51-C93242C2E2FD Q39455595-77BC8934-363C-466F-9D45-2EEDB660C00A Q39512887-4CC67AB6-101A-4BD8-AC4D-EEFC3C9CFDE5 Q40652722-4E6D2072-8083-4D19-8C02-D20D1CD6634D Q41875708-9B1808F6-FA9F-4E9E-A6A8-9B3F257C85E6 Q42324150-1F9D41AA-D977-448C-A2A4-9494AD527321 Q42792218-25AC6D38-6713-47D3-A315-61FEC566BE50 Q43013998-0703CF50-5838-4442-BF08-0B535C14117F Q43224619-F5592E4C-6FBA-4768-A3AC-C5EDE0EC8A8E Q44491619-29462B57-E7D8-41FF-AA2A-1EB18AD6C63E Q46835462-3F26AB70-7CD0-4504-A6BD-F29508E57D65 Q47691053-615F4550-196A-4704-8A22-790A56CAC7B6

P2860

Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic.

http://www.wikidata.org/entity/Q36404922

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Experimental and clinical phar ...... testinal selective antibiotic.

@ast

Experimental and clinical phar ...... testinal selective antibiotic.

@en

type

label

Experimental and clinical phar ...... testinal selective antibiotic.

@ast

Experimental and clinical phar ...... testinal selective antibiotic.

@en

prefLabel

Experimental and clinical phar ...... testinal selective antibiotic.

@ast

Experimental and clinical phar ...... testinal selective antibiotic.

@en

P1433

Q36404922-0021C151-F338-4C27-80D8-EF0BA0841E3E

P1476

Q36404922-86072D36-4355-4E29-949F-27264EE5BD99

P2093

Q36404922-8A422DEF-CAC9-49C8-974E-084EC95762F5

Q36404922-BDEB4432-5389-4E28-8B32-A379BC8AE4C6

P2860

Q36404922-02C4D722-4745-4453-94B8-5A4A0D355995

Q36404922-04AC0D73-C476-40AF-AF11-544B41BF7ED7

Q36404922-1A404330-B7B7-49FE-A16D-202AA7948E27

Q36404922-24E5DC63-138D-4AEA-9597-E57BB96DE30A

Q36404922-31E464DC-29F9-4B89-81EE-BE92131B80BF

Q36404922-3D990F4E-8BB1-4D62-8093-76D75DC0CB25

Q36404922-431F56BC-B305-4074-BE50-D5C2D24ED3C0

Q36404922-752E143A-E1B1-4B1F-B509-59565861B845

Q36404922-78E03CD6-718E-465A-A428-4B2684CCAFEA

Q36404922-7A06E7E5-1A8F-4072-91F9-1159C3291C37

P304

Q36404922-2A27C7ED-DA55-486E-9689-B1256E9FE51F

P31

Q36404922-2A15D8F2-03E0-4982-BCEB-6F6FCDA44E18

P356

Q36404922-9ADFCBA0-ED85-434A-B4C3-6AF846C04616

P478

Q36404922-4A4DEC43-B7FE-491C-A2E7-70CFFA4B99A1

P577

Q36404922-524BD796-3D8D-4A31-9A64-C975B819ACD2

P698

Q36404922-1B6E2BBA-D7B3-499B-98D9-CB1D499EF65B

P356

P1433

P1476

Experimental and clinical phar ...... testinal selective antibiotic.

@en

P2093

Carmelo Scarpignato

http://www.w3.org/2001/XMLSchema#string

Iva Pelosini

http://www.w3.org/2001/XMLSchema#string

P2860

Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective

Practice guidelines for the management of infectious diarrhea.

Drug interactions between oral contraceptives and antibiotics.

Pseudomembranous colitis: causes and cures.

In vitro activity and fecal concentration of rifaximin after oral administration

Gastrointestinal infections.

Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.

In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species.

Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci.

Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative.

P304

13-27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000089776

http://www.w3.org/2001/XMLSchema#string

P478

73 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2006-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16498249

http://www.w3.org/2001/XMLSchema#string